文献速递类风湿关节炎

类风湿关节炎达标治疗前后的不良事件与资源使用:一项随机对照试验的事后分析

Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2019-07-19

该事后分析利用18个月整群随机对照试验中6家诊所的数据,比较类风湿关节炎患者达标治疗干预前(第1-9个月)与干预期间(第10-18个月)的不良事件和资源使用。结果显示干预前后不良事件记录率相似(10.2% vs 8.8%,P=0.41),风湿科就诊次数、实验室监测和诊断影像在干预期间未增加。

要点

  • 达标治疗干预前后不良事件记录率相似(10.2% vs 8.8%,P=0.41)。
  • 干预期间风湿科就诊次数少于干预前(均值4.0 vs 3.6,P=0.02)。
  • 干预期间伴随监测实验室检查的就诊比例低于干预前(90.0% vs 52.7%,P<0.001)。

核心结论

  • 达标治疗实施前后不良事件发生率相似,风湿科就诊、实验室监测和诊断影像在达标治疗干预期间未增加。

研究设计与样本

  • 研究类型为18个月整群随机对照试验的事后分析,纳入6家诊所的数据,比较达标治疗干预前(第1-9个月)与干预期间(第10-18个月)的不良事件和资源使用。
  • 不良事件和资源使用结局基于对类风湿关节炎患者所有风湿科就诊的病历回顾。

主要发现

  • 干预前审查了321例患者的记录,干预期间审查了315例患者的记录。
  • 干预前10.2%的就诊记录了不良事件,干预期间为8.8%(P=0.41)。
  • 干预前53.6%的患者使用生物制剂改善病情抗风湿药,干预期间为49.8%(P=0.73)。
  • 干预前风湿科就诊次数均值±标准差为4.0±1.4,干预期间为3.6±1.2(P=0.02)。
  • 干预前90.0%的就诊伴随监测实验室检查,干预期间为52.7%(P<0.001);干预前15.4%的就诊包含诊断影像,干预期间为8.9%(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Treat-to-target (TTT) is an accepted paradigm for care of patients with rheumatoid arthritis (RA). Because TTT can be associated with more medication switches, concerns arise regarding whether implementing TTT may increase adverse events and/or resource use. The aim of this study was to examine adverse events and resource use during the preintervention and intervention periods of the TTT intervention trial. METHODS: We used data from 6 practices enrolled in an 18-month cluster-randomized controlled trial to compare adverse events and resource use before (months 1-9) and during (months 10-18) a TTT intervention. The outcomes of interest, adverse events and resource use, were based on medical record review of all rheumatology visits for RA patients before and during the intervention. RESULTS: We examined records for 321 patients before the intervention and 315 during the intervention. An adverse event was recorded in 10.2% of visits before the intervention and 8.8% of visits during the intervention (P = 0.41). Biologic disease-modifying antirheumatic drugs were taken by 53.6% of patients before the intervention and 49.8% of patients during the intervention (P = 0.73). Rheumatology visits were more frequent before the intervention (mean ± SD 4.0 ± 1.4) than during the intervention (mean ± SD 3.6 ± 1.2; P = 0.02). More visits were accompanied by monitoring laboratory tests before the intervention (90.0%) compared with during the intervention (52.7%; P < 0.001). A greater percentage of visits before the intervention included diagnostic imaging (15.4%) versus during the intervention (8.9%; P < 0.001). CONCLUSION: We observed similar rates of adverse events before and during the implementation of TTT for RA. Rheumatology visits, use of laboratory monitoring, and diagnostic imaging did not increase during the TTT intervention.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Solomon DH, Yu Z, Katz JN, et al. Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2019. PMID: 30221841. doi:10.1002/acr.23755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。